Phase I/II Clinical Trial of LBL-015 for Injection

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

December 5, 2023

Study Completion Date

December 5, 2023

Conditions
Advanced Malignant Tumor
Interventions
DRUG

LBL-015 for Injections

Initial dose - MTD ; Q2W ; intravenous infusion

Trial Locations (6)

200123

Shanghai East Hospital, Shanghai

233000

The First Affiliated Hospital of Bengbu Medical College, Bengbu

250117

Shandong Cancer Hospital, Jinan

330000

The First Affiliated Hospital of Nanchang University, Nanchang

410031

Hunan Cancer Hospital, Changsha

450003

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
collaborator

Shanghai East Hospital

OTHER

collaborator

Shandong Cancer Hospital and Institute

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Hunan Cancer Hospital

OTHER

collaborator

The First Affiliated Hospital of Nanchang University

OTHER

collaborator

The First Affiliated Hospital of Bengbu Medical University

OTHER

lead

Nanjing Leads Biolabs Co.,Ltd

INDUSTRY

NCT05107011 - Phase I/II Clinical Trial of LBL-015 for Injection | Biotech Hunter | Biotech Hunter